PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.27%
Negative revenue growth while Medical - Pharmaceuticals median is 2.18%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-4.56%
Negative gross profit growth while Medical - Pharmaceuticals median is 1.10%. Seth Klarman would suspect poor product pricing or inefficient production.
-25.71%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-29.63%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-26.28%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-26.27%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-26.27%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.00%
Share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.01%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.93%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 37.56%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
66.65%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 15.35%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
33.46%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 11.28%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.85%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 26.93% over a decade. Joel Greenblatt might see a standout compounder of earnings.
40.83%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 12.38%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-8.53%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
No Data
No Data available this quarter, please select a different quarter.
126.08%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 6.76%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
59.09%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 7.64%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
42.86%
3Y dividend/share CAGR of 42.86% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
67.36%
AR growth of 67.36% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
2.88%
Inventory growth of 2.88% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
1.82%
Asset growth of 1.82% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
2.86%
BV/share growth of 2.86% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-4.54%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
2.21%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.